The immunosuppressive effect of MYCN expression in cancers, including neuroblastoma and lung cancer, is well known [45–47], and Masso-Valles et al. reported that MYCN inhibition may be a potential cancer immunotherapy [45]. This evidence concerns the gene MYCN and lung cancer.